Responses
Clinical/translational cancer immunotherapy
Original research
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.